Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151401, Punjab, India.
Department of Human Genetics and Molecular Medicine, School of Health Sciences, Central University of Punjab, Bathinda, 151401, Punjab, India.
Eur J Med Chem. 2023 Nov 5;259:115699. doi: 10.1016/j.ejmech.2023.115699. Epub 2023 Jul 30.
Malaria is among one of the most devastating and deadliest parasitic disease in the world claiming millions of lives every year around the globe. It is a mosquito-borne infectious disease caused by various species of the parasitic protozoan of the genus Plasmodium. The indiscriminate exploitation of the clinically used antimalarial drugs led to the development of various drug-resistant and multidrug-resistant strains of plasmodium which severely reduces the therapeutic effectiveness of most frontline medicines. Therefore, there is urgent need to develop novel structural classes of antimalarial agents acting with unique mechanism of action(s). In this context, design and development of hybrid molecules containing pharmacophoric features of different lead molecules in a single entity represents a unique strategy for the development of next-generation antimalarial drugs. Research efforts by the scientific community over the past few years has led to the identification and development of several heterocyclic small molecules as antimalarial agents with high potency, less toxicity and desired efficacy. Triazole derivatives have become indispensable units in the medicinal chemistry due to their diverse spectrum of biological profiles and many triazole based hybrids and conjugates have demonstrated potential in vitro and in vivo antimalarial activities. The manuscript compiled recent developments in the medicinal chemistry of triazole based small heterocyclic molecules as antimalarial agents and discusses various reported biologically active compounds to lay the groundwork for the rationale design and discovery of triazole based antimalarial compounds. The article emphasised on biological activities, structure activity relationships, and molecular docking studies of various triazole based hybrids with heterocycles such as quinoline, artemisinins, naphthyl, naphthoquinone, etc. as potential antimalarial agents which could act on the dual stage and multi stage of the parasitic life cycle.
疟疾是世界上最具破坏性和致命性的寄生虫病之一,每年在全球范围内夺走数百万人的生命。它是一种由各种疟原虫属寄生虫引起的蚊媒传染病。临床上使用的抗疟药物的滥用导致了各种耐药性和多药耐药性疟原虫株的出现,这严重降低了大多数一线药物的治疗效果。因此,迫切需要开发具有独特作用机制的新型结构类别抗疟药物。在这种情况下,设计和开发包含单个实体中不同先导分子药效团特征的杂合分子代表了开发下一代抗疟药物的独特策略。科学界在过去几年中的研究努力导致了几种杂环小分子的鉴定和开发,这些小分子作为具有高活性、低毒性和所需疗效的抗疟药物。由于其广泛的生物分布谱,三唑衍生物已成为药物化学中不可或缺的单元,许多基于三唑的杂合和缀合物已在体外和体内显示出抗疟活性。本文综述了基于三唑的小分子杂环作为抗疟药物的药物化学最新进展,并讨论了各种报道的具有生物活性的化合物,为基于三唑的抗疟化合物的合理设计和发现奠定基础。本文强调了具有生物活性的各种基于三唑的杂合与杂环(如喹啉、青蒿素、萘基、萘醌等)的结构-活性关系和分子对接研究,作为可能的抗疟药物,可作用于寄生虫生命周期的双阶段和多阶段。